Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis

Phase 2 Completed 104 enrolled Betanien Hospital Norwegian Foundation for Health and Rehabilitation · collab University of Oslo · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the safety and efficacy of gonadotropin-releasing hormone (GnRH) antagonist therapy versus placebo in patients with moderate to severe rheumatoid arthritis.

Timeline

Start: 2008-05
Primary completion: 2011-06
Completion: 2011-10

Outcome

Met primary endpoint

paper DAS28-CRP), improved with cetrorelix compared with placebo by day 5 (-1.0 vs. -0.4, P = 0∙010). PMID 26460564 ↗

Publications

Kass A, Hollan I, Fagerland MW, Gulseth HC, Torjesen PA, Forre OT. Rapid Anti-Inflammatory Effects of Gonadotropin-Releasing Hormone Antagonism in Rheumatoid Arthritis Patients with High Gonadotropin Levels in the AGRA Trial. PLoS One. 2015 Oct 13;10(10):e0139439. doi: 10.1371/journal.pone.0139439. eCollection 2015.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetrorelix	Other / unclassified	3 mg	Subcutaneous